CS b-Bioactive® is the most thoroughly researched chondroitin sulfate on the market and was developed by Bioiberica, S.A.U., Spain. Its efficacy and safety has been tested in 20 clinical studies and 14 million patients treated worldwide.
The original chondroitin sulfate (CS b-Bioactive®) is a non-interchangeable complex biological substance. The European Medicines Agency (EMA) classifies chondroitin sulfate as a complex biological substance and therefore not interchangeable with other chondroitin molecules obtained from different manufacturing processes and/or from raw materials with different characteristics. This is why, although chondroitin sulfate (CS b-Bioactive®) has been marketed as a therapeutic drug in many European countries since early 90s, there are no generic (copied) versions of chondroitin sulfate on the market and therefore not all chondroitin products have the same clinical effects.
Why is CS b-Bioactive® different?
Unique molecular properties
CS b-Bioactive® manufacturing process ensures highly purified, consistent molecule with unique physicochemical properties that result in greater absorption and efficacy.
Better absorption and greater clinical effects
Comparative studies have demonstrated that CS b-Bioactive® is better absorbed and induces a more powerful anti-inflammatory effect on the joints, while some chondroitin molecules are less effective and even produce undesired effect, such as pro-inflammatory action of the joints.
No. 1 researched chondroitin
It has been tested in more than 20 clinical trials (5,000 patients) and in a total of 43 scientific studies with proven effectiveness in osteoarthritis, psoriasis and other chronic inflammatory diseases.
Highest quality and safety
CS b-Bioactive® is manufactured to the highest pharmaceutical standards and exceeds the quality requirements of both the European Pharmacopoeia (EP) and the United States Pharmacopoeia (USP).